Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480387 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
A Phase 2 study of Treatment of Hepatitis C, sponsored by Peter J. Ruane, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02480387 is a Phase 2 study of Treatment of Hepatitis C that has completed, run by Peter J. Ruane, M.D.. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02480387, a Phase 2 study of Treatment of Hepatitis C, has completed, sponsored by Peter J. Ruane, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA \< 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- Treatment: treatment
Conditions Studied
Interventions
- DRUG Ledipasvir/Sofosbuvir FDC
Study Locations (1)
California
- Peter J. Ruane, MD, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02480387
The ClinicalTrials.gov registry entry for NCT02480387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter J. Ruane, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment of Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Ledipasvir/Sofosbuvir FDC is the first listed.
NCT02480387 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02480387 about?
NCT02480387 is a clinical study titled "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection". Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA \< 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- T...
What is the current status of trial NCT02480387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-05. Estimated completion is 2016-01.
What conditions does trial NCT02480387 study?
This clinical trial studies the following conditions: Treatment of Hepatitis C.
What interventions are being tested in trial NCT02480387?
The interventions under investigation include: Ledipasvir/Sofosbuvir FDC (DRUG).
Who is sponsoring clinical trial NCT02480387?
This trial is sponsored by Peter J. Ruane, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02480387 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.